NDATOPICALCREAMPriority Review
Approved
Nov 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
SILVADENE (silver sulfadiazine) by Pfizer is clinical pharmacology silver sulfadiazine has broad antimicrobial activity. First approved in 1973.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SILVADENE (silver sulfadiazine) is a topical sulfonamide antibacterial cream approved in 1973 for treating burn wounds and radiation-induced dermatitis. It exerts broad-spectrum antimicrobial activity by acting on bacterial cell walls to inhibit gram-negative and gram-positive bacteria as well as yeast, including organisms resistant to other antimicrobial agents.
$0.031BPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal commercial momentum ($31K Part D spend), indicating small and consolidating brand teams focused on maintaining legacy market share.
Mechanism of Action
CLINICAL PHARMACOLOGY Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram-negative and gram-positive bacteria as well as being effective against yeast. Results from in vitro testing are listed below. Sufficient data have been obtained to demonstrate that silver…
Pharmacologic Class:
Sulfonamide Antibacterial
Indications
Worked on SILVADENE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.